Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel poliglumex
Drug: paclitaxel

First Posted Date: 2007-10-31

Last Posted Date: 2020-10-05

Lead Sponsor: CTI BioPharma

Target Recruit Count: 450

Registration Number: NCT00551733

Locations: 🇺🇸
Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center, Burbank, California, United States
🇺🇸
Clinical Trials and Research Associates, Incorporated, Montebello, California, United States
🇺🇸
Broward Oncology Associates, Fort Lauderdale, Florida, United States

and more 38 locations

Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: bevacizumab
Drug: carboplatin
Drug: erlotinib hydrochloride
Drug: paclitaxel
Genetic: gene expression analysis
Genetic: protein expression analysis
Genetic: proteomic profiling
Other: laboratory biomarker analysis

First Posted Date: 2007-10-30

Last Posted Date: 2017-06-08

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 116

Registration Number: NCT00550537

Locations: 🇺🇸
University of Florida Shands Cancer Center, Gainesville, Florida, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 4 locations

Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 1

Withdrawn

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy
Drug: sorafenib tosylate

First Posted Date: 2007-10-22

Last Posted Date: 2019-01-10

Lead Sponsor: University of Texas Southwestern Medical Center

Registration Number: NCT00547443

Locations: 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸
Arlington Cancer Center - Arlington, Arlington, Texas, United States

Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

Phase 1

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: nab-paclitaxel
Radiation: Radiation therapy

First Posted Date: 2007-10-16

Last Posted Date: 2014-06-09

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 13

Registration Number: NCT00544648

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center at Franklin, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Purchase Cancer Group - Paducah, Paducah, Kentucky, United States

and more 3 locations

Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Metastatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2007-10-08

Last Posted Date: 2011-09-21

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 50

Registration Number: NCT00541138

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Carcinoma

Interventions: Drug: Albumin-bound paclitaxel
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2007-10-08

Last Posted Date: 2019-10-29

Lead Sponsor: Celgene

Target Recruit Count: 1052

Registration Number: NCT00540514

Locations: 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸
Robert A. Moss, MD, FACP, Inc., Fountain Valley, California, United States
🇺🇸
Mercy Hospital, Portland, Maine, United States

and more 34 locations

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

Phase 2

Terminated

Conditions: Neuroblastoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Melphalan
Procedure: Stem Cell Infusion
Device: ClinicMACS

First Posted Date: 2007-10-04

Last Posted Date: 2019-07-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00539500

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Paclitaxel
Drug: AZD2171
Drug: Carboplatin

First Posted Date: 2007-10-04

Last Posted Date: 2011-06-01

Lead Sponsor: AstraZeneca

Target Recruit Count: 6

Registration Number: NCT00539331

Locations: 🇯🇵
Research Site, Tokyo, Japan

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Not Applicable

Completed

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Childhood Acute Lymphoblastic Leukemia in Remission

Interventions: Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Drug: busulfan
Radiation: total-body irradiation
Drug: carboplatin
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Drug: carmustine
Drug: thiotepa
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2007-09-28

Last Posted Date: 2021-04-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 174

Registration Number: NCT00536601

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Phase 1

Completed

Conditions: Adult Solid Neoplasm
BRCA1 Mutation Carrier
BRCA2 Mutation Carrier
Hereditary Breast and Ovarian Cancer Syndrome

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2007-09-26

Last Posted Date: 2015-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 107

Registration Number: NCT00535119

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy